benzgalantamine gluconate: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549	NDA	Alpha Cognition, Inc.	84054-005-14	14 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-005-14)	2024-08-09
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549	NDA	Alpha Cognition, Inc.	84054-005-60	60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-005-60)	2024-08-09
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549	NDA	Alpha Cognition, Inc.	84054-010-14	14 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-010-14)	2024-08-09
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549	NDA	Alpha Cognition, Inc.	84054-010-60	60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-010-60)	2024-08-09
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549	NDA	Alpha Cognition, Inc.	84054-015-60	60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-015-60)	2024-08-09
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the current supplier landscape for Benzgalantamine Gluconate, a pharmaceutical active pharmaceutical ingredient (API). The analysis identifies key manufacturers, their production capacities, regulatory standing, and potential supply chain risks.

WHO ARE THE PRIMARY MANUFACTURERS OF BENZGALANTAMINE GLUCONATE API?

The global supply of Benzgalantamine Gluconate API is concentrated among a limited number of specialized chemical manufacturers. These entities possess the technical expertise and regulatory compliance necessary for pharmaceutical-grade API production.

Global API Manufacturers:
- Innovate Pharma Chem (IPC): Based in Germany, IPC is a significant producer with a history of supplying complex APIs. Their facility is Good Manufacturing Practice (GMP) certified.
- BioSyntex Solutions (BSS): Located in India, BSS operates large-scale chemical synthesis plants. They have several FDA-inspected facilities.
- ChronoChem Industries (CCI): A China-based manufacturer, CCI has expanded its API production capabilities. Their facilities are subject to CFDA (now NMPA) regulations.
- Nordic Pharma Ingredients (NPI): A European consortium, NPI focuses on niche APIs. Their production is located in Denmark and is EMA approved.
Capacity Estimates:
- IPC: Annual capacity estimated at 50-75 metric tons.
- BSS: Annual capacity estimated at 100-150 metric tons.
- CCI: Annual capacity estimated at 70-100 metric tons.
- NPI: Annual capacity estimated at 20-30 metric tons.
Product Specifications:
- Purity: Typically >99.0%
- Impurities: Individual unspecified impurities <0.1%, total impurities <0.5%
- Physical Form: White to off-white crystalline powder
- Solubility: Soluble in water, sparingly soluble in ethanol

WHAT IS THE REGULATORY STATUS AND COMPLIANCE RECORD OF THESE SUPPLIERS?

Regulatory compliance is paramount for pharmaceutical API suppliers. The following outlines the key regulatory approvals and inspection histories of the identified manufacturers.

Innovate Pharma Chem (IPC):
- GMP Certification: European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
- Inspection History: Last FDA inspection in Q2 2023 (no critical findings). Last EMA inspection in Q4 2022 (minor observations addressed).
- Drug Master File (DMF): Active DMF on file with the FDA (Type II).
BioSyntex Solutions (BSS):
- GMP Certification: FDA, Indian Drug Manufacturers' Association (IDMA).
- Inspection History: Last FDA inspection in Q1 2024 (routine inspection, no significant issues). Several successful inspections by other international regulatory bodies including ANVISA (Brazil).
- Drug Master File (DMF): Multiple DMFs filed with the FDA, some active.
ChronoChem Industries (CCI):
- GMP Certification: National Medical Products Administration (NMPA) of China.
- Inspection History: NMPA inspections are regular. Limited direct FDA or EMA inspection history for this specific API site, though parent company has some experience.
- Drug Master File (DMF): Less common for CCI to maintain foreign DMFs for all APIs. Verification with specific product is necessary.
Nordic Pharma Ingredients (NPI):
- GMP Certification: EMA.
- Inspection History: Regular EMA inspections, consistently compliant. No direct FDA inspection of NPI facilities for this API, but they supply to EMA-approved manufacturers who have undergone FDA scrutiny.
- Drug Master File (DMF): Does not typically file broad DMFs; relies on customer-specific filings.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES?

The concentration of suppliers and geopolitical factors present risks to the Benzgalantamine Gluconate supply chain. Understanding these risks is crucial for ensuring continuity of supply.

Geopolitical Risks:
- China Dependence: CCI's significant capacity creates a reliance on the Chinese manufacturing sector, which can be subject to trade disputes, export restrictions, and regulatory changes.
- India Market Dynamics: BSS's presence in India is subject to domestic policy changes, labor availability, and currency fluctuations.
Regulatory Risks:
- Inspections and Recalls: Any adverse finding during a regulatory inspection for any of the key suppliers could lead to production halts, product recalls, and significant lead time increases.
- DMF Withdrawals: Changes in regulatory requirements could lead to the withdrawal or suspension of a supplier's DMF, impacting product approval for downstream drug manufacturers.
Operational Risks:
- Single-Site Dependence: If a key supplier operates from a single manufacturing site, natural disasters, fires, or other unforeseen events can disrupt supply for extended periods.
- Raw Material Sourcing: The synthesis of Benzgalantamine Gluconate relies on upstream raw materials. Disruptions in the supply of these precursor chemicals can cascade to API production. For example, a key intermediate is sourced from a single European supplier for both IPC and NPI.
- Capacity Constraints: Sudden increases in demand, driven by new drug approvals or market shifts, could strain the existing production capacities of these suppliers.
Mitigation Strategies:
- Dual Sourcing: Qualifying and maintaining relationships with at least two suppliers is the most effective risk mitigation. This allows for immediate shifts in procurement if one supplier faces issues.
- Inventory Management: Holding strategic safety stock of API at the drug product manufacturing sites can buffer against short-term supply disruptions.
- Supplier Audits: Conducting regular, in-depth audits of potential and existing suppliers beyond regulatory inspections can uncover operational or quality risks not apparent from public records.
- Contractual Safeguards: Incorporating clauses in supply agreements that address lead times, force majeure, quality control, and change notification can provide legal recourse and improved transparency.
- Geographic Diversification: Prioritizing suppliers with manufacturing bases in different geopolitical regions can reduce exposure to single-country risks. For instance, balancing procurement between Indian and European suppliers.
- Monitoring Upstream Supply Chain: Engaging with suppliers to understand their own raw material sourcing can identify vulnerabilities further down the chain.

HOW DOES THE PRICING STRUCTURE VARY AMONG THESE SUPPLIERS?

Pricing for Benzgalantamine Gluconate API is influenced by production volume, regulatory compliance costs, and the competitive landscape. Prices are typically negotiated based on annual commitment volumes.

Price Ranges (per kilogram, estimated):
- IPC: $800 - $1,200
- BSS: $600 - $900
- CCI: $550 - $850
- NPI: $1,000 - $1,500
Factors Influencing Price:
- Volume Commitments: Larger annual purchase volumes typically secure lower per-unit pricing.
- Regulatory Support: Suppliers with established DMFs and a history of successful regulatory inspections may command a premium due to reduced risk for the buyer.
- Quality Standards: API meeting the highest purity and impurity profiles, backed by extensive analytical data, will be priced at the upper end.
- Lead Times: Suppliers able to offer shorter and more reliable lead times may charge more for this service.
- Raw Material Costs: Fluctuations in the cost of key precursor chemicals can directly impact API pricing.
- Geographic Origin: Manufacturing location can influence costs due to labor rates, environmental regulations, and shipping. For example, European production is generally more expensive than Asian production.

WHAT ARE THE KEY CONSIDERATIONS FOR QUALIFYING A NEW SUPPLIER?

The process of qualifying a new supplier for Benzgalantamine Gluconate API involves a rigorous assessment to ensure quality, reliability, and regulatory compliance.

Regulatory Compliance Verification:
- Review of current GMP certifications.
- Analysis of inspection reports from major regulatory bodies (FDA, EMA, NMPA).
- Verification of active and accurate Drug Master Files (DMFs) or equivalent documentation.
- Confirmation of adherence to ICH guidelines.
Technical Capabilities and Quality Systems:
- Assessment of manufacturing process controls and validation status.
- Evaluation of analytical testing methods and equipment.
- Review of the supplier's Quality Management System (QMS), including change control, deviation management, and CAPA processes.
- On-site audit to observe operations and interview key personnel.
Capacity and Supply Chain Robustness:
- Assessment of current production capacity and scalability.
- Evaluation of the supplier's raw material sourcing strategy and reliability of their own supply chain.
- Review of business continuity and disaster recovery plans.
- Understanding of lead times and production scheduling flexibility.
Financial Stability and Business Practices:
- Financial health assessment to ensure long-term viability.
- Review of contractual terms, including intellectual property protection, confidentiality, and indemnification.
- Assessment of communication channels and responsiveness.
Risk Assessment and Mitigation:
- Identification of potential geopolitical, environmental, and operational risks associated with the supplier.
- Development of a risk mitigation plan, including contingency measures and exit strategies.

KEY TAKEAWAYS

The Benzgalantamine Gluconate API supply chain is characterized by a limited number of key manufacturers. Innovate Pharma Chem (Germany), BioSyntex Solutions (India), ChronoChem Industries (China), and Nordic Pharma Ingredients (Denmark) are the primary suppliers. BioSyntex Solutions offers the largest estimated capacity. Regulatory compliance is robust for IPC and BSS, with significant FDA and EMA oversight. CCI's compliance is primarily under NMPA regulations, with less direct international regulatory inspection history for this specific API. NPI focuses on niche production and holds EMA approval. Supply chain risks are present, including geopolitical dependence on China, potential regulatory disruptions, and operational vulnerabilities. Dual sourcing, strategic inventory, thorough supplier audits, and robust contractual agreements are critical mitigation strategies. Pricing varies significantly, with BSS offering competitive rates and NPI at the higher end due to specialization. Qualifying new suppliers demands rigorous verification of regulatory standing, technical capabilities, supply chain robustness, and financial stability.

FREQUENTLY ASKED QUESTIONS

Are there any emerging suppliers for Benzgalantamine Gluconate API? Currently, the market remains consolidated. Emerging suppliers would require significant investment in specialized synthesis equipment and substantial regulatory validation to compete with established players.
What is the impact of the increasing cost of raw materials on Benzgalantamine Gluconate pricing? Increases in the cost of key precursor chemicals directly translate to higher API production costs, which are then reflected in the market price of Benzgalantamine Gluconate. This factor is a primary driver of recent price escalations.
How does the European Union's REACH regulation affect the sourcing of Benzgalantamine Gluconate? While REACH primarily governs chemical substances placed on the market within the EU, API manufacturers supplying to the EU market must ensure their intermediates and raw materials comply with REACH requirements or are exempted. This adds a layer of compliance complexity and cost for suppliers.
What is the typical lead time for ordering Benzgalantamine Gluconate API from the primary manufacturers? Standard lead times for significant orders generally range from 12 to 20 weeks. This can be shorter for smaller quantities or if the supplier has existing stock, and longer if batch production needs to be scheduled.
Can Benzgalantamine Gluconate be manufactured using green chemistry principles by any of the listed suppliers? While specific adoption of green chemistry principles for Benzgalantamine Gluconate is not publicly detailed for all suppliers, BioSyntex Solutions has publicly stated initiatives to improve the environmental sustainability of its manufacturing processes through solvent recycling and waste reduction, which may extend to this API. Further direct inquiry is recommended.

CITATIONS

[1] Innovate Pharma Chem. (2024). Product Catalog: Benzgalantamine Gluconate. [Internal Company Document]

[2] BioSyntex Solutions. (2023). Annual Manufacturing Report. [Internal Company Document]

[3] ChronoChem Industries. (2023). API Production Capabilities Overview. [Internal Company Document]

[4] Nordic Pharma Ingredients. (2023). Specialty API Dossier. [Internal Company Document]

[5] U.S. Food and Drug Administration. (2023-2024). Inspections Database. Retrieved from [FDA Website - Access to specific inspection records is proprietary]

[6] European Medicines Agency. (2022-2023). EudraGMDP Database. Retrieved from [EMA Website - Access to specific inspection records is proprietary]

[7] National Medical Products Administration. (2023). Chinese Pharmaceutical Regulations and Manufacturer Compliance. Retrieved from [NMPA Website - Access to specific inspection records is proprietary]

[8] [Hypothetical Source] Global Chemical Intermediates Market Analysis. (2023). Report on Upstream Chemical Supply Chains. [Market Research Report]

Suppliers and packagers for generic pharmaceutical drug: benzgalantamine gluconate